NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2193.50 30.30 (1.40%)

Near 52W High of ₹2297.90

542.8K NSE+BSE Volume

NSE 13 Apr, 2026 2:18 PM (IST)

61,900.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2193.50

1.40%

Sustainability of cost curbs key to boost earnings growth

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark’s Q3FY26 revenue growth was led by India biz, while US growth was muted post adjusted for USD 18mn of milestone income. Gross margin was lower by 259bps YoY due to unfavourable product and geographical mix, though cost curbs drove 131bps expansion in EBITDA margin.

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2193.50

1.40%

Mixed quarter; domestic strengthens

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted largely in-line financial performance in 3QFY26. The quarterly performance was driven by a healthy revival in the domestic formulation (DF) business, out-licensing income related to ISB2001, and better performance in emerging markets.

Glenmark Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Glenmark Pharmaceuticals Ltd.

18 Nov 2025

2193.50

1.40%

Exceptional Q2 buoyed by ISB-2001 income and sharp margin expansion.

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300.

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

17 Nov 2025

2193.50

1.40%

Tough quarter led by GST shock and operational reset

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered a miss on 2QFY26 earnings, adjusted for a one-time upfront payment received from Abbvie. The miss was largely driven by a severe impact on the domestic formulation (DF) business following the GST transition.

Glenmark Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Glenmark Pharmaceuticals Ltd.

09 Sep 2025

2193.50

1.40%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives....

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

02 Sep 2025

2193.50

1.40%

Growth momentum and margin stability expected from H2FY26E

Buy: Glenmark Pharmaceuticals Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

19 Aug 2025

2193.50

1.40%

Base biz struggle continues; ISB 2001 deal holds valuation

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) Q1FY26 performance was below our expectation due to muted show across regions. Rise in other operating income inflated margins and PAT.

Glenmark Pharma has gained 59.17% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

18 Aug 2025

2193.50

1.40%

Weak 1QFY26 performance

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) reported a lower-than-expected performance in 1QFY26, as revenue/EBITDA/PAT came in 9%/14%/15% below our estimates.

Glenmark Pharmaceuti.. has an average target of 2121.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

18 Jul 2025

2193.50

1.40%

ISB 2001 deal well-done; valuation defies uncertainties ahead

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) subsidiary Ichnos Glenmark Innovation (IGI) has out-licensed its oncology asset ISB 2001 to Abbvie in a deal valued at USD 1.925bn, including USD 700mn upfront, USD 1.225bn in milestones and tiered doubledigit royalty on net sales.

Glenmark Pharmaceuticals Ltd.'s price crossed below 30Day SMA today

Glenmark Pharmaceuticals Ltd.

11 Jul 2025

2193.50

1.40%

Stock Flash

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of Glenmark
Pharmaceuticals, has entered into an exclusive global licensing agreement
with AbbVie for the development and commercialization of IGI’s lead
oncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecific
antibody is currently in Phase 1 clinical trials for relapsed/refractory multiple
myeloma (R/R MM).

Glenmark Pharma has gained 59.17% in the last 1 Year

Is Glenmark Pharmaceuticals Ltd. worth buying?

581 Votes:

Buy 79.52%

Sell 13.6%

Hold 6.88%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf